Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade combination chemotherapy in relapsed or refractory AL amyloidosis
ISRCTN33283585Phase 2Terminated
- Sponsor
- University College London
- Start
- Dec 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of bortezomib in light-chain amyloidosis (2 arms), sponsored by University College London. Primary endpoints: Clonal response of the underlying plasma cell dyscrasia and Safety and toxicity of PAD and CVD. Started Dec 2010; status: terminated.
02
Drugs
bortezomib
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ISRCTN33283585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN33283585.